CPX-351, a drug therapy for acute myeloid leukemia, has been raised by the U.S. Food and Drug Administration, FDA, to orphan drug status. Now with seven years market exclusivity in the U.S, Celator Pharmaceuticals will continue through to phase 2 clinical trials.
According to medcitynews.com, its goals involve a fund of $5 million, and $2.57m of this target has been raised through equity, options and securities so far.
Understand how governments are collaborating to improve the orphan drugs challenges, learn the strategic solutions, and discover the trends of technology investments at the World Orphan Drugs Congress USA 2012.
The congress' speakers consist of business and scientific industry leaders from North America and beyond.
Register now, and meet decision-makers from big pharma, early stage and mid stage biotechs, government and regulatory bodies.